“Results from a second Phase III alopecia areata study are anticipated in the third quarter, followed by regulatory submission starting later this year.”

In context

“regrowth across both Rinvoq doses compared to placebo. Baseline scalp coverage prior to treatment was approximately 16%. In the Rinvoq 30-milligram group, 54% of patients reached 80% or more scalp hair coverage and 47% reached 90% or more coverage at 24 weeks. A robust effect was also demonstrated with Rinvoq 15 milligrams. These are truly transformative results and compare very favorably to the efficacy shown in pivotal trials for other JAK inhibitors. The placebo-adjusted SALT 20 and 10 scores for Rinvoq 30 milligrams were approximately 20 percentage points above the rates for the highest approved doses of other JAK inhibitors. For the Rinvoq 15-milligram group, rates were approximately 10 points above. We are very pleased with these results, which certainly surpassed our expectations. Results from a second Phase III alopecia areata study are anticipated in the third quarter, followed by regulatory submission starting later this year. The vitiligo program for Rinvoq is also nearing completion with top line results from Phase III studies expected later this year. External innovation has supported expansion of our growing immunology pipeline. We recently announced plans to acquire Capstan. Their novel platform allows for in vivo programming of cells through mRNA delivery using targeted lipid nanoparticles. Capstan's lead asset currently in Phase I generates CD19-specific CD8-positive in vivo CAR T cells. The CAR T cells are designed to achieve rapid and deep B-cell depletion without the need for lymphoablating chemotherapy while also avoiding other challenges associated with conventional ex vivo CAR-Ts. This innovative approach has the potential to become a transformative new treatment modality to reset the immune system”